clinical trial · NCT05495464
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
M.D. Anderson Cancer Center·early phase1·active not recruiting·n = 22
LymphomaMantle Cell LymphomaAcalabrutinibRituximabBrexucabtagene AutoleucelCyclophosphamideFludarabine Phosphate
brief summary
To learn if giving acalabrutinib, rituximab, and brexucabtagene autoleucel to patients with previously untreated high-risk mantle cell lymphoma (MCL) can help to control the disease.
started
Nov 18, 2022
primary completion
Mar 31, 2027
completion
Mar 31, 2027
last updated
Feb 27, 2026
detailed description
PRIMARY OBJECTIVES:
To determine the safety profile of the acalabrutinib plus rituximab combination followed by CAR T-cell therapy in newly diagnosed high risk MCL patients.
SECONDARY OBJECTIVES:
To evaluate efficacy measured by complete response (CR) rate and progression free survival (PFS) of the acalabrutinib plus rituximab combination followed by CAR T-cell therapy in newly diagnosed high risk MCL patients.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol